BioSante completes individual enrollment in LibiGel Stage III trial against HSDD BioSante Pharmaceuticals, Inc . today announced that enrollment of topics in the next of two pivotal Stage III LibiGel protection and efficacy trials offers been completed. Enrollment in the 1st LibiGel efficacy trial was finished in February. The efficacy trials are becoming executed under an FDA-accepted special protocol evaluation contract. LibiGel is in advancement for the treating feminine sexual dysfunction , particularly, hypoactive libido disorder in menopausal ladies, for which there is absolutely no FDA-approved item.

For the treating LEMS in December 2009 and may be the first approved treatment because of this indication, thereby conferring orphan medication protection and providing a decade of marketplace exclusivity in European countries. Related StoriesRaising lupus recognition: an interview with Professor Ramsey-Goldman, MDPhenotyping human illnesses in mice: an interview with Professor Carola Vinuesa The release of Firdapse brings the 1st specifically approved treatment choice for LEMS to sufferers in the E.U. And marks our 4th commercial product available.S., and we also continue steadily to measure the best development technique for this product in additional indications in the U.S.